webinar register page

Webinar banner
Expanding access to monoclonal antibodies for HIV prevention
Hosted by The Global HIV Vaccine Enterprise in partnership with IAVI.

Although several mAbs targeting infectious diseases are licensed, there is a huge access gap, with 80% of the sale taking place in the US, Canada and Europe while 85% of the population at most risk of infectious diseases living in low- and middle- income countries.

After decades of research and development a safe and globally effective HIV vaccine remains a challenge. However, new strategic approaches including passive immunisation, are in clinical development (e.g. the AMP study) and may significantly contribute to HIV prevention strategies.

With a rapidly increasing pipeline of new mAb-based products for HIV and other infectious diseases, planning for how to bring these products to people that need them most is critical.

The Webinar aims to review the recommendations outlined in the IAVI-Wellcome Trust report on Expanding Access to Monoclonal Antibody-based Products through the lens of HIV prevention and ask, in the context of the AMP study, how can the global community work together to ensure global access to future bnAbs for HIV prevention.

A short video introducing the report can be watched here: https://www.youtube.com/watch?v=yvR3e0ZZutk

The Webinar features an introduction from Mark Feinberg, CEO and President of IAVI, followed by perspectives of a renowned panel of experts on R&D, manufacturing, access, policy and regulation, and a 30-minute audience Q&A.

Nov 23, 2020 04:00 PM in Zurich

Webinar is over, you cannot register now. If you have any questions, please contact Webinar host: Vaccine Enterprise.